Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002900 · ClinicalTrials.gov registry record

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

A clinical trial of Breast Cancer and Cardiac Toxicity, sponsored by SWOG Cancer Research Network.

Completed
Registry status
180
Enrollment target
20
Study locations

NCT00002900: Completed study of Breast Cancer and Cardiac Toxicity, sponsored by SWOG Cancer Research Network.

NCT00002900 is a study of Breast Cancer and Cardiac Toxicity that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 180 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002900, a study of Breast Cancer and Cardiac Toxicity, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
180 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are undergoing treatment on the SWOG-8897 clinical trial.

Interventions

  • PROCEDURE management of therapy complications

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Veterans Affairs Medical Center - Long Beach - Long Beach
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • Veterans Affairs Medical Center - West Los Angeles - Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
  • Veterans Affairs Outpatient Clinic - Martinez - Martinez
  • CCOP - Bay Area Tumor Institute - Oakland
  • Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Cancer Center - Sacramento
  • UCSF Comprehensive Cancer Center - San Francisco
  • CCOP - Santa Rosa Memorial Hospital - Santa Rosa
  • David Grant Medical Center - Travis Air Force Base

Arizona

  • CCOP - Western Regional, Arizona - Phoenix
  • Veterans Affairs Medical Center - Phoenix (Carl T. Hayden) - Phoenix
  • Veterans Affairs Medical Center - Tucson - Tucson
  • Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock
  • Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock

Alabama

  • MBCCOP - Gulf Coast - Mobile

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center - Denver

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 1997-02
SWOG Cancer Research Network

270 total trials

What the finished NCT00002900 record still lists

NCT00002900 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which management of therapy complications is the first listed.

NCT00002900 names 20 study sites across 5 states, led by California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00002900 about?

NCT00002900 is a clinical study titled "SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are under...

What is the current status of trial NCT00002900?

This trial is currently completed. The enrollment target is 180 participants. The study started on 1997-02.

What conditions does trial NCT00002900 study?

This clinical trial studies the following conditions: Breast Cancer, Cardiac Toxicity.

What interventions are being tested in trial NCT00002900?

The interventions under investigation include: management of therapy complications (PROCEDURE).

Who is sponsoring clinical trial NCT00002900?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002900 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002900's enrollment target sits among peer trials

180 406th of 1224 higher than 817 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002900, the US trial registry maintained by the National Library of Medicine. NCT00002900 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.